MNCs, Corporates to Enter Pharma Retail (India)
This article was originally published in PharmAsia News
Executive Summary
India's drug retail industry may be moving toward consolidation as large Indian companies as well as global players are looking to it for major opportunities. Today India's drug retail market generates 450 billion rupees per year and is handled by around 550,000 operations. Hong Kong-based Zuellig Pharma and U.S.-based Cardinal Health are rumored to be eyeing opportunities to expand in India. Zuellig Pharma is one of Asia's largest drug logistics providers, and views India as "a major market with vast potential," says Nike Ampton, managing director of Zuellig Pharma India. India's Reliance Anil Dhirubhai Ambani Group is investing 12 billion rupees to build a large drug distribution network in India. Reliance Industries retail arm Reliance Retail in India says it may begin purchasing drugs directly from pharmaceutical manufacturers as a way to comb out spurious products. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.